PharmValidateThe numbers behind the signatures on your validation protocols.
The Validation Floor Has Moved.
Three concurrent pressures are redefining what regulators expect when they walk into your manufacturing facility. The first is process analytical technology — FDA reviewers now arrive with data scientists who ask why your CPP corridors were set without multivariate analysis. The second is the accelerated approval pathway: molecules that earned breakthrough designation are reaching commercial scale in timelines that would have been considered reckless a decade ago. The third is data integrity enforcement, which has quietly become the lens through which every other finding is amplified.
The consequence is that a validation package that would have sailed through a pre-approval inspection in 2019 now generates a Form 483 observation on its second page. Not because the science changed — because the expectation of documented process understanding changed. Regulators want to see that you know why your process works, not merely that it has worked three times.
"The FDA's 2025 process validation guidance update is not a paperwork revision. It is a structural expectation that manufacturers demonstrate real-time process understanding — not retrospective batch averaging."
The manufacturers navigating this successfully share one characteristic: they stopped treating validation as a documentation exercise and started treating it as a knowledge management exercise. The protocol is the artifact. The understanding is the asset. When a regulator asks why you chose that dissolution endpoint, the answer cannot begin with "historical precedent."
CDMOs face a compounding version of this problem. Each new molecule onboarding carries its own regulatory history, its own sponsor expectations, and its own tech transfer risk profile. The organizations that complete transfers cleanly — no post-transfer failures, no PAI delays — are those that conducted structured knowledge transfer before the first engineering batch, not after the third process performance qualification batch deviated.
ICH Q8/Q10 integration with real-time release testing frameworks and CPP/CQA linkage documentation.
Structured gap analysis against the receiving site's equipment train before the first engineering batch is scheduled.
Audit trail completeness and ALCOA+ compliance reviewed at the system level, not the SOP level.
The people who have already stood in your control room.
Each consultant carries direct regulatory-facing experience — not advisory distance. Their authored insights below are drawn from active engagements, not conference abstracts.
Twenty-six years across small molecule and biologics manufacturing, including twelve as a site validation lead at a major CMO. Has authored or reviewed over 200 PPQ protocols and presented at PDA Annual Meeting on continued process verification program design.
Why Your CPV Program Is Generating Data You're Not Using
Most continued process verification programs were designed to satisfy the requirement, not to generate insight. The result is a monthly trending report that nobody reads until a deviation forces the issue. The programs that actually function as an early warning system share three design choices: they trend at the batch level rather than the aggregate level, they include control chart rules that are pre-defined rather than retrospectively applied, and they are owned by manufacturing science rather than quality assurance. The distinction matters because QA ownership optimizes for compliance. Manufacturing science ownership optimizes for understanding.
Specialist in multi-product facility cleaning validation programs with particular focus on shared equipment trains and MACO limit justification under EMA and FDA frameworks. Developed the cleaning validation remediation strategy for three CDMO sites following 483 observations.
MACO Limits That Survive Regulatory Scrutiny
The most common cleaning validation observation in FDA 483s issued between 2023 and 2025 was not about swab recovery — it was about the scientific justification for the acceptable limit itself. Facilities that set limits based on 1/1000th of the minimum therapeutic dose without a toxicological assessment are now receiving observations that require a full program remediation. The solution is not more conservative limits. It is a documented, defensible rationale that begins with the pharmacological and toxicological profile of the worst-case product and works forward to a site-specific, equipment-specific limit. The calculation is secondary to the justification.
Former FDA investigator turned industry consultant. Led data integrity remediation programs at four multinational manufacturers following Warning Letters. Specializes in audit trail architecture, hybrid system validation, and MES implementation qualification in regulated environments.
The Audit Trail Gap That Precedes Every Warning Letter
In reviewing data integrity Warning Letters issued since 2022, a consistent pattern emerges: the observation that triggers the enforcement action is rarely the original deviation. It is the discovery that the audit trail was either disabled, not reviewed, or not configured to capture the relevant metadata. A compliant audit trail is not the same as a reviewed audit trail. Organizations that have moved from paper to electronic systems without establishing a formal audit trail review procedure have created a compliance gap that is invisible until an investigator asks to see the last six months of reviews. The answer "we have audit trails enabled" is not the answer they are looking for.
Fourteen years in pharmaceutical development and scale-up, including five years at a global CDMO managing oncology product transfers from clinical to commercial manufacturing. Developed a structured tech transfer readiness framework now used across three client sites.
The Knowledge Transfer That Happens Too Late
The most expensive moment in a tech transfer is the third engineering batch. By that point, the receiving site has already committed equipment time, raw material inventory, and analyst bandwidth to a process that could have been better characterized at the sending site. The organizations that transfer cleanly conduct a formal process knowledge assessment before the technology transfer agreement is signed — not after. This assessment identifies the gaps in process understanding that the sending site has learned to work around: the blending endpoint that is operator-dependent, the granulation that is sensitive to ambient humidity in ways that are not in the batch record. These are the transfers that generate PAI observations. The knowledge was always there. It was never transferred.
Where the in-house team ends.
Most manufacturing organizations have the operational depth to run the process. The validation science layer — the protocols, the regulatory strategy, the data architecture — is where specialist coverage matters.
Coverage reflects senior-consultant-level engagement, not subcontracted generalist support. Every engagement is staffed by a named principal with direct regulatory-facing experience in the relevant discipline.
Engagements where the outcome was not hypothetical.
All case studies are anonymized per client confidentiality agreements. Metrics are drawn from engagement close-out reports and client-verified outcomes.
Oncology injectable transfer: zero post-transfer failures across 18 commercial batches
A mid-size CDMO was onboarding a high-potency injectable from a sponsor whose development team had limited commercial scale-up experience. The technology transfer package contained significant gaps in CPP characterization, and the receiving site's equipment train differed materially from the sending site.
PharmValidate conducted a structured process knowledge assessment at the sending site before the first engineering batch was scheduled. Identified seven undocumented process sensitivities, including a fill-weight variability driver tied to a pump seal characteristic that was not captured in the batch record. Developed a revised CPP corridor document and updated the process validation strategy to reflect the receiving site's equipment specifications.
Engineering batches completed without deviation. PPQ executed on schedule. PAI conducted 14 months after engagement start — no observations related to tech transfer package.
483 response accepted: data integrity remediation program closed in 11 months
A contract manufacturer received a Form 483 with four data integrity observations following an FDA inspection, including findings related to audit trail configuration, access control, and the use of shared login credentials in a LIMS environment. The site had received a previous 483 on related issues two years prior.
Thomas Fairweather led a system-level gap assessment across eight computerized systems, prioritizing by regulatory risk. Developed a remediation roadmap with 34 action items, staffed three items requiring external system vendor coordination, and authored the 483 response on behalf of the site quality team.
FDA accepted the 483 response without requesting a follow-up inspection. Remediation program closed 11 months after engagement start. Site has since completed two additional inspections without data integrity observations.
Continued process verification program redesigned: 6 OOS investigations eliminated in first year
A large oral solid dosage manufacturer had an active CPV program that was generating monthly trending reports but was not functioning as an early warning system. Six out-of-specification investigations in an 18-month period had each been attributed to assignable causes that, in retrospect, were visible in the CPV data weeks before the OOS event.
David Marchetti reviewed the existing CPV program design and identified three structural issues: trending at the aggregate level rather than the batch level, absence of pre-defined control chart rules, and QA ownership that optimized for report generation rather than process insight. Redesigned the program with batch-level trending, Western Electric rules pre-approved by the site quality director, and transferred program ownership to the manufacturing science function.
No OOS investigations in the 12 months following program redesign. Two process signals identified and investigated proactively — both addressed through equipment preventive maintenance before they generated batch failures.
Pre-Approval Inspection Readiness Assessment.
A proprietary 47-point audit checklist developed from our direct experience supporting FDA and EMA pre-approval inspections. Organized by discipline — process validation, data integrity, cleaning validation, and tech transfer — with a scoring framework that identifies your highest-risk gaps before the investigator does.
- 47 audit-ready checkpoints across four validation disciplines
- Risk-scoring matrix aligned to current FDA inspection priorities
- Annotated with regulatory citations (21 CFR Parts 211/820, EU GMP Annex 15)
- Delivered as a structured PDF — ready for internal review or consultant use
No marketing sequence. One email with the PDF attached.